VCEL - Vericel Corporation
About Vericel Corporation (https://vcel.com)
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Dominick C. Colangelo | Chief Executive Officer, President & Director | 1964 | $1,735,451 USD |
| Michael Halpin | Chief Operating Officer | 1962 | $913,869 USD |
| Joseph Anthony Mara Jr. | Chief Financial Officer & Treasurer | 1976 | $854,869 USD |
| Jonathan Hopper FRCSEd. | Chief Medical Officer | 1962 | $755,885 USD |
| Sean C. Flynn | Chief Legal Officer | 1974 | $740,669 USD |
| Eric Burns | Vice President of Finance & Investor Relations | – | – |
| Jonathan Siegal | Principal Accounting Officer, Vice President & Corporate Controller | – | – |
| Mike Gilligan | Senior Vice President of Sales | – | – |
| Patrick J. Fowler | Senior Vice President of Corporate Development & Strategy | – | – |
| Roland DeAngelis | Chief Marketing Officer | – | – |